Tian Zhichao, Yao Weitao
Department of Orthopedics, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China.
Front Oncol. 2022 Feb 10;12:815900. doi: 10.3389/fonc.2022.815900. eCollection 2022.
Taxanes (paclitaxel and docetaxel) play an important role in the treatment of advanced sarcomas. Albumin-bound paclitaxel (nab-paclitaxel) is a new kind of taxane and has many advantages compared with paclitaxel and docetaxel. Nab-paclitaxel is currently approved for the treatment of advanced breast, non-small cell lung, and pancreatic cancers. However, the efficacy of nab-paclitaxel in sarcomas has not been reviewed. In this review, we first compare the similarities and differences among nab-paclitaxel, paclitaxel, and docetaxel and then summarize the efficacy of nab-paclitaxel against various non-sarcoma malignancies based on clinical trials with reported results. The efficacy and clinical research progress on nab-paclitaxel in sarcomas are also summarized. This review will serve as a good reference for the application of nab-paclitaxel in clinical sarcoma treatment studies and the design of clinical trials.
紫杉烷类（紫杉醇和多西他赛）在晚期肉瘤的治疗中发挥着重要作用。白蛋白结合型紫杉醇（纳米白蛋白结合型紫杉醇）是一种新型紫杉烷类药物，与紫杉醇和多西他赛相比具有许多优势。纳米白蛋白结合型紫杉醇目前已被批准用于治疗晚期乳腺癌、非小细胞肺癌和胰腺癌。然而，纳米白蛋白结合型紫杉醇在肉瘤中的疗效尚未得到综述。在本综述中，我们首先比较纳米白蛋白结合型紫杉醇、紫杉醇和多西他赛之间的异同，然后根据已报道结果的临床试验总结纳米白蛋白结合型紫杉醇对各种非肉瘤恶性肿瘤的疗效。还总结了纳米白蛋白结合型紫杉醇在肉瘤中的疗效及临床研究进展。本综述将为纳米白蛋白结合型紫杉醇在临床肉瘤治疗研究中的应用及临床试验设计提供良好参考。
